NL-OMON54481招募中不适用
Determination of neutrophils response to gluten and development of a novel less invasive assay to diagnose gluten-related diseases. - Neutrophil migration in gluten-related diseases (Granrose).
适应症
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 入组人数
- 40
研究概览
简要总结
Trial ended prematurely
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 18 至 64（—）
入选标准
- •Age: 20-60 years old
- •Furthermore:
- •- Biopsy proven celiac disease patients in remission, on a strict gluten-free
- •diet since at least 3 months
- •- Non-celiac gluten sensitive (NCGS) patients, reporting gastrointestinal or
- •extra-intestinal symptoms within 8 hours after gluten consumption, in whom
- •celiac disease has been ruled out by means of serology and/or biopsy, and on a
- •gluten-free diet since at least 3 months
- •- Healthy volunteers without celiac disease or NCGS, who do not state any
- •symptoms after ingesting gluten
排除标准
- •- Gastrointestinal, genitourinary or immune diseases that can affect
- •interpretation of the results
- •- Pregnancy
- •- Use of antibiotics or immunosuppressive drugs within 90 days prior to the
- •- Excessive use of drugs or alcohol
- •- Participation in any other scientific study that may interfere with the
- •present study
研究者
相似试验
尚未招募
不适用
eutrophil migration in gluten-related diseasesCeliac diseaseNL-OMON29405Maastricht University40
已完成
2 期
An initiative to find a new treatment to Celiac disease.CTRI/2018/03/012624Dr Ajit Sood15
尚未招募
不适用
How well do tests that measure gluten in the faeces detect low-level dietary gluten exposure in people with coeliac disease?ACTRN12620000259943A/Professor Jason Tye-Din50
招募中
不适用
to diagnose the kidney injury in early stages by a biomarkerCTRI/2014/09/004971Indian Council of Medical Research400
进行中（未招募）
不适用
Phase IV study to investigate neutrophil downregulation of Thy-1 by Raptiva® (Efalizumab) as a potential responder predictor in patients with moderate to severe plaque psoriasis - Responder Prediction StudyModerate to severe chronic plaque psoriasis (PASI = 12) failing to respond to, or with a contraindication to, or intolerant to other systemic therapies including cyclosporine, methotrexate and Psoralen ultraviolet light A (PUVA)MedDRA version: 8.1Level: LLTClassification code 10050576Term: Psoriasis vulgarisEUCTR2006-004547-35-DESerono GmbH